Noile-Immune Biotech,, a spin-out of Yamaguchi University founded in 2015, has tied up with Takeda Pharmaceuticals on antigen receptor expressing T cell (CAR-T) therapy. Noile- Immune Biotech holds the exclusive license on a patent on the augmentation of gene-engineered T cell function for appropriate expansion, accumulation, and inducible memory function to solid cancer issued to Yamaguchi University. The contract was concluded through Takeda’s subsidiary Millenium Pharmaceuticals Co. and includes R&D by Noile-Immune personnel done at Takeda’s Shonan Research Institute in Kanagawa Prefecture.

Takeda Pharmaceutical news release, September 5, 2017